Interv Akut Kardiol. 2005;4(4):218-222

ANTICOAGULANT THERAPY DURING CORONARY ANGIOPLASTY

Ivo Varvařovský
Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice

Anticoagulant therapy is used for prevention of thrombotic complications during coronary angioplasty (PCI). In the last decade, antiplatelet therapy has widely been studied in large randomized trials, while anticoagulant therapy for PCI has remained unaddressed. Optimal anticoagulant treatment therefore remains a pending question. In this review, the role of unfractionated heparin and novel agents in the setting of coronary angioplasty is summarized.

Keywords: Key words: coronary angioplasty, anticoagulant therapy, heparin, low molecular weight heparin, direct thrombin inhibitors, factor Xa inhibitors.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. ANTICOAGULANT THERAPY DURING CORONARY ANGIOPLASTY. Interv Akut Kardiol. 2005;4(4):218-222.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-68. Go to original source... Go to PubMed...
    2. Popma JJ, Weitz J, Bittl JA. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114: 728S-741S. Go to original source... Go to PubMed...
    3. Hirsh J, Anand SS, Halperin JL. Guide to anticoagulant therapy: Heparin. A statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994-3018. Go to original source...
    4. Narins CR, Hillegass WB, Nelson CL. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-71. Go to original source... Go to PubMed...
    5. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998; 82: 50P-56P. Go to original source... Go to PubMed...
    6. Popma JJ, Prpic R, Lansky AJ. Heparin dosing in patients undergoing coronary intervention. Am J Cardiol 1998; 82: 19P-24P. Go to original source... Go to PubMed...
    7. Moscucci M, Mansour KA, Kent KC. Peripheral vascular complications of directional coronary atherectomy and stenting: predictors, management and outcome. Am J Cardiol 1994; 74: 448-53. Go to original source... Go to PubMed...
    8. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998; 82(8B): 50P-56P. Go to original source... Go to PubMed...
    9. Hirsh J, Warkentin TE, Shaughnessy SG. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S. Go to original source... Go to PubMed...
    10. Levine MN, Hirsh J, Gent M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56. Go to original source...
    11. Ranucci M, Isgro G, Cazzaniga A. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204. Go to original source... Go to PubMed...
    12. Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol 2003; 9: 125-131. Go to PubMed...
    13. Young E, Prins M, Levine MN. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643. Go to original source... Go to PubMed...
    14. Chiu HM, Hirsh J, Yung WL. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-184. Go to original source...
    15. Altmann DB, Racz M, Battleman DS. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2422 patients. Am Heart J 1996; 132: 503-507. Go to original source... Go to PubMed...
    16. Waksman R, King SB, Douglas JS. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol 1995; 75: 886-889. Go to original source... Go to PubMed...
    17. Rinder MR, Tamirisa PK, Taniuchi M. Safety and efficacy of suture-mediated closure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 54: 146-151. Go to original source... Go to PubMed...
    18. Ashby DT, Dangas G, Aymong EA. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol 2003; 92: 319-322. Go to original source... Go to PubMed...
    19. Vainer J, Fleisch M, Gunnes P. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996; 78: 964-966. Go to original source... Go to PubMed...
    20. Kaluski E, Krakover R, Cotter G. Minimal heparinization in coronary angioplasty-how much heparin is really warranted? Am J Cardiol 2000; 85: 953-956. Go to original source... Go to PubMed...
    21. Denardo SJ, Davis KE, Reid PR. Efficacy and safety of minimal dose (< or = 1.000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 2003; 91: 1-5. Go to original source... Go to PubMed...
    22. Denardo SJ, Davis KE, Tcheng JE. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 2005; 149: 138-144. Go to original source... Go to PubMed...
    23. Chew DP, Bhatt DL, Lincoff AM. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-966. Go to original source... Go to PubMed...
    24. Hanratty CG, Ward M. Optimal activated clotting time during percutaneous coronary intervention. Circulation 2001; 104: e83. Go to original source... Go to PubMed...
    25. Tolleson TR, O Shea JC, Bittl JA. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observation from the ESPRIT trial. J Am Coll Cardiol 2003; 41: 386-393. Go to original source... Go to PubMed...
    26. Vuillemenot A, Schiele F, Meneveau N. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemostat 1999; 81: 214-220. Go to original source... Go to PubMed...
    27. Mehta SR, Steg PG, Granger CB. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention (ASPIRE Pilot Trial). Circulation 2005; 111: 1390-7139. Go to original source... Go to PubMed...
    28. Becker RC, Alexander JH, Dyke C. Effect of the novel direct factor Xa inhibitor DX9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res 2005: v tisku. Go to original source... Go to PubMed...
    29. Kaiser B, Jeske W, Walenga JM. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinolysis 1999; 10: 495-501. Go to original source... Go to PubMed...
    30. Dyke CR, Becker RC, Kleiman NS. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-2391. Go to original source... Go to PubMed...
    31. Alexander JH, Yang H, Becker RC. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 2005; 3: 439-447. Go to original source... Go to PubMed...
    32. Alexander JH, Dyke CK, Yang H. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 2: 234-241. Go to original source... Go to PubMed...
    33. Karsch KR, Preisack MB, Baildon R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled multicenter trial (REDUCE trial). J Am Coll Cardiol 1996; 28: 1437-1443. Go to original source... Go to PubMed...
    34. Rabah MM, Premmereur J, Graham M. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391-1395. Go to original source... Go to PubMed...
    35. Kereiakes DJ, Kleiman NS, Fry E. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141: 348-352. Go to original source... Go to PubMed...
    36. Kereiakes DJ, Grines C, Fry E. Enoxaparin and abciximab adjunctive pharmacotherapy during percutanous coronary intervention. J Invasive Cardiol 2001; 13: 272-278. Go to PubMed...
    37. Choussat R, Montalescot G, Collet JP. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40: 1943-1950. Go to original source... Go to PubMed...
    38. Chen WH, Lau CP, Lau YK. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutanous coronary intervention. J Invasive Cardiol 2002; 14: 439-442. Go to PubMed...
    39. Aslam MS, Sundberg S, Sabri MN. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002; 57: 187-190. Go to original source... Go to PubMed...
    40. Wong GC, Giugliano RP, Altman EM. Use of low-molecular-weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331-342. Go to original source... Go to PubMed...
    41. Ferguson JJ, Califf RM, Antman EM. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54. Go to original source... Go to PubMed...
    42. Madan M, Radhakrishnan S, Reis M. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005; 95: 1295-1301. Go to original source... Go to PubMed...
    43. Bittl JA, Strony J, Brinker JA. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-769. Go to original source... Go to PubMed...
    44. Bittl JA, Chaitman BR, Feit F. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J 2001; 142: 952-959. Go to original source... Go to PubMed...
    45. Lincoff AM, Kleiman NS, Kottke-Marchant K. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-853. Go to original source... Go to PubMed...
    46. Lincoff AM, Bittl JA, Kleiman NS. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004; 93: 1092-1096. Go to original source... Go to PubMed...
    47. Lincoff AM, Bittl JA, Harrington RA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863. Go to original source... Go to PubMed...
    48. The Direct Trombin Inhibitor Trialists Collaborative Group. Direct trombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients data. Lancet 2002; 359: 294-302. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.